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Introduction
The leading causes of death in the United
States include ischemic heart diseases, diabetes
mellitus and chronic kidney disease (CKD),
among others1. While these chronic diseases
are multifactorial, the development of many
diseases and the risk for all-cause mortality are
derived in part from lifestyle factors including
diet2-4. Considerable attention has recently
been given to the role of gut microbiota in
chronic disease, as well as how diet modulates
the human enterotype5-7. Over the last decade,
research on mechanisms of chronic disease
have revealed an obligate role for gut
microbiota in production of pro-atherogenic
species including trimethylamine N-oxide
(TMAO)5,8. TMAO is produced after
phosphatidylcholine and related metabolites
are converted by host microbiota to
trimethylamine, which undergoes further
oxidation in the liver by flavin monooxygenase
enzymes (FMOs)9-11. This article reviews the
proposed mechanisms by which TMAO may
contribute to atherosclerosis and chronic
disease risk. Special attention is given to the
role of diet in modulating the human
enterotype as well as the therapeutic viability
of dietary regulation in modifying chronic
disease risk.
TMAO Synthesis
A study published in 2011 by Wang et al.
identified a molecular pathway by which
phosphatidylcholine is converted to choline
and metabolized by gut microbiota to
trimethylamine (TMA)9. After absorption of
TMA into host circulation, hepatic enzymes
further oxidize this species, producing TMAO9.
Specifically, flavin monooxygenase 3 (FMO3)
carries out this oxidation and displays the
greatest specificity towards TMA12. Further
characterization of this purported mechanism
has revealed that other phosphatidylcholine-
related species such as L-carnitine and betaine
also result in the production of TMAO via
conversion to TMA as an intermediate10,13. This
mechanism of TMA production has recently
been revised for L-carnitine, as the
intermediate gamma-butyrobetaine (GBB) is
generated before conversion to TMA in
humans11.
Elucidating the interplay between diet and
TMAO synthesis is important, as plasma TMAO
levels are associated with cardiovascular
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disease (CVD) risk and mortality in a dose-
dependent manner14. Observational studies
have also revealed that TMAO levels are
predictive of major adverse cardiac events
(MACEs) in certain population cohorts;
specifically, Li et al. found that, in patients
presenting to the emergency department with
symptoms of chest pain, plasma TMAO levels
were independently predictive of future
MACEs15. Diet and the human enterotype are
intrinsically linked to TMAO synthesis, as
choline-containing species are converted to
TMAO by gut microbiota9,11. Furthermore,
animal products are largely implicated in
TMAO production, as both choline and L-
carnitine are concentrated in foods such as
meat, dairy and eggs9,16. Interestingly, the
choline derivative betaine is foundmore largely
concentrated in plant foods and is associated
with CVD risk when there is a concomitant rise
in TMAO levels17,18.
TMAO Mechanismof Action in Atherosclerosis
Rather than serving as a biomarker for a
diet high in saturated fat and cholesterol,
TMAO has been characterized in many studies
as an contributer to atherosclerosis. These
studies have implicated TMAO in lipid
metabolism dysfunction and inhibition of
reverse cholesterol transport (RCT) as well as
multiple inflammatory mechanisms19.
Wang et. al discovered that dietary
supplementation of phosphatidylcholine-
derived metabolites to atherosclerosis-prone
mice resulted in increased expression of the
macrophage scavenger receptors CD36 and SR-
A19. These macrophage-specific receptors then
facilitate creation of foam cells—macrophages
which engulf oxidized low density lipoprotein
(LDL) and contribute to the formation of
atherosclerotic plaques9,20. Importantly, high
levels of dietary choline induced macrophage
foam cell formation in a microbiota-dependent
fashion, as mice treated with broad spectrum
antibiotics show complete mediation of this
phenotype9. Additionally, TMAO has also been
found to increase risk of thrombosis and
modulate platelet hyperreactivity in mouse
models21.
Experimental data suggests that the
capacity of gut microbiota to generate TMAO is
important in atherosclerosis progression9,22. A
study published by Gregory et al. demonstrated
that mice receiving large-intestine microbial
transplants from atherosclerosis-prone donor
mice had increased incidence of atherosclerosis
compared to those receiving microbial
transplants from atherosclerosis-resistant
mice22. Recently, a CD36-dependent pathway
has been identified whereby TMAO stimulates
macrophage migration and foam cell
formation. SiRNA-mediated knockdown of the
cell-surface receptor CD36 subsequently
downregulated these processes and inhibited
foam cell formation. The action of enzymes
including MAPK (mitogen activated protein
kinase) and JNK (jun N-terminal kinase) in a
downstream signaling pathway were also
shown to be necessary for foam cell
formation23. Several other pathways of
inflammation and immune responses to TMAO
have also been explored, including activation of
atherosclerosis-promoting proteins by nuclear
factor-kB19,24.
Studies suggest that TMAO also modulates
gene expression of certain cholesterol
transporters and other enzymes regulating bile
synthesis in mice, leading to a reduction in the
total bile acid pool and inhibition of reverse
cholesterol transport (RCT)10,19,25. Koeth et al
found that cholesterol transporter expression
was reduced in enterocytes after dietary TMAO
supplementation. Furthermore, dietary TMAO
supplementation altered gene expression
(mRNA levels) of cholesterol transporters in
enterocytes, hepatocytes and macrophages10.
These findings reveal how TMAO might affect
cholesterol elimination at multiple levels, as
well as how TMAO can lead to inhibition of
RCT10. Interestingly, FMO3 also plays an
important and independent role in lipid
metabolism, as targeted knockdown of FMO3
results in increased non-biliary macrophage
RCT and restoration of cholesterol
equilibrium26. Taken together, these results
suggest that TMAO may increase cholesterol
deposition in peripheral tissues due to
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decreased elimination and RCT, resulting in
injury to the arterial endothelium and
atherosclerotic plaque formation. Upregulation
of macrophage scavenger receptor expression
may increase engulfment of LDL cholesterol
and foam cell formation, further exacerbating
this process.
Surprisingly, one study in mice found that
TMAO slowed aortic lesion development.
Collins et al. purport that TMAO may actually
have a protective effect on arterial function,
preventing atherosclerosis27. Additionally, one
review questioned the role of TMAO as a
deleterious molecule, as TMAO is used as an
osmolyte in marine animals, and fish (TMAO-
producing) consumption is associated with
health benefits28. Observational studies have
also found considerable intra-individual
differences in TMAO levels independent of
diet28. While these findings seem to challenge
the best available balance of evidence, the role
of TMAO in atherosclerosis may need further
clarification.
TMAO in Other Chronic Diseases
Recent evidence has implicated TMAO in
other chronic disease processes. In 2006, Bain
et al. discovered TMA and TMAO accumulation
in the blood of patients with end-stage renal
disease prior to hemodialysis treatment29.
While TMA and TMAO normalized to healthly
levels following dialysis, their accumulation
continued before subsequent treatment. Years
later, a cohort with chronic kidney disease
(CKD) was found to have elevated TMAO levels
in blood plasma independently associated with
increased risk for MACEs30. Further studies
found increased TMAO-associated risk for all-
cause mortality in those with CKD, as TMAO
has been identified as an independent predictor
of systemic inflammation and mortality in
these patients31,32. Another study showed that
TMAO levels are also inversely correlated with
glomerular filtration rate (GFR), an indicator of
kidney function33. While these results suggest a
causal relationship between TMAO and kidney
function, interpretation is complicated by renal
clearance of TMAO. Elevated TMAO in patients
with CKD may simply result from pre-existing
kidney dysfunction and subsequent TMAO
retention34. On the contrary, some animal
studies suggest TMAO may promote renal
fibrosis and vascular calcification31,35. Recent
studies in rats identified TMAO-associated
vascular calcification via the NLRP3 and
nuclear factor-kB signaling pathways, but
further investigation in humans is warranted35.
A number of recent studies have also
identified a causal relationship between TMAO
and type-2 diabetes (T2D). Li et al. showed that
increases in phosphatidylcholine consumption
were associated with greater risk of T2D in
three large prospective cohorts36. Further
studies reported up to 10-fold increases in
blood plasma TMAO levels in diabetic mice
compared to wild-type littermate controls.
Additionally, these mice displayed an increased
body mass index (BMI), and TMAO levels
increased with age in both diabetic mice and
controls37. This study also identified a trend
between TMAO levels and diabetes status in
human patients: individuals with prediabetes
had higher TMAO levels than those with
normal glucose tolerance, and those with frank
T2D had the highest circulating TMAO, though
this data was not statistically significant.
Subsequent research in younger cohorts has
found no association between TMAO levels and
increased T2D risk, and only a modest increase
in prediabetes prevalence in a non-linear
fashion for men and women 20-55 years
old38,39. These results may suggest that a
decline in renal function is key to linking TMAO
and conditions including T2D. As T2D is a risk
factor for kidney disease, progressive renal
dysfunction may reduce TMAO clearance and
signal adverse metabolic events already
underway38. Associations between increasing
age and TMAO levels may support this
conclusion, as declining kidney function and
increased insulin resistance may happen
independently of TMAO action. General gut
dysbiosis is indeed implicated in T2D, but the
role of TMAO as an effector of these processes
is not currently evident40. While the role of
TMAO in atherosclerosis and CVD is better
characterized, further interventional studies
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are needed to characterize a potential causal
relationship between TMAO and other chronic
diseases.
Diet and TMAO Synthesis
Diet plays an important role in TMA/TMAO
production, as the precursors for TMA
synthesis are derived from food9,10. Both
choline and L-carnitine are concentrated in
animal products; however, the contribution of
these foods to chronic disease risk through
TMAO production has remained controversial.
Koeth et al. first identified a decreased
capacity for vegans and vegetarians to generate
TMAO in their 2013 study10. Postprandial
(“post-meal”) TMAO production after an L-
carnitine supplement was significantly reduced
for both vegans and vegetarians when
compared to omnivores. Fasting TMAO levels
were also lower in this cohort. One subject who
followed a vegan diet for more than five years
undertook an L-carnitine challenge and had
almost no capacity to generate TMAO as well as
nominal fasting plasma and urine TMAO
levels10. Recent evidence suggests this
phenomenon may be due to diet-dependent
conversion of the intermediate GBB to TMA11.
This study identified that both omnivores and
vegans/vegetarians rapidly convert L-carnitine
to GBB, but omnivores have a much greater
capacity to subsequently metabolize GBB to
TMA. These results suggest that omnivores and
vegans cultivate enterotypes with varying
capacities to metabolize GBB to TMA. Wu et al.
independently reported similar results: after an
oral carnitine challenge test (OCCT), omnivores
had a much greater capacity to generate TMAO
than the vegetarian subjects in the study41.
Interestingly, some long-term vegetarians still
demonstrated a remarkable ability to generate
TMAO after the OCCT, which may be due to
continued consumption of eggs and dairy41.
Recently, diet-dependent taxonomic shifts
in microbiome composition have been
investigated for those on plant-based versus
animal product-based diets7. David et al. found
that switching between plant-based and
animal product-based diets can rapidly alter
the gut microbiome in as little as one day. One
vegetarian subject in the study transitioned
from a Prevotella-rich microbiome to a
predominantly Bacteroides-rich microbiome
after just four days on an animal product-
based diet7. Interestingly, a Prevotella-rich
microbiome has been associated with increased
synthesis of short-chain fatty acids (SCFA)
implicated in suppression of inflammation and
cancer42. A Prevotella-rich gut microbiome
across vegetarians and vegans has indeed been
corroborated by other studies and may stem
from a higher intake of dietary fiber41,43,44.
Many researchers have investigated the
effects of Mediterranean diets (MDs) on TMAO
synthesis, as MDs are often associated with
reduced risk for chronic disease45. Some studies
suggest MDs may lower TMAO production, but
results have varied. Griffin et al. found that a 6-
month MD intervention did not significantly
alter plasma TMAO levels in a cohort of healthy
adult males46. Other studies have also
suggested this dietary intervention may not
significantly alter fasting TMAO levels, but that
postprandial TMAO levels may be more
sensitive to dietary intake. Conversely, one
study showed that MDs lower TMAO levels
when compared to a high-fat Atkins diet, but
both were outperformed by an Ornish-style
plant-based diet47. Indeed, a landmark 1990
study by Ornish et al. showed that a plant-
based diet and other healthy lifestyle behaviors
were sufficient to reverse atherosclerotic lesion
size in those with coronary artery disease48.
The efficacy of a MD could depend on the
relative consumption of fruits, vegetables and
plant foods to animal products implicated in
TMAO production.
Together, these studies may suggest that a
low-fat, plant-based diet provides the best
therapeutic dietary intervention to reduce
TMAO production. Indeed, patients suffering
from trimethylaminuria (caused by mutations
in FMO3 which disrupt TMA metabolism49,50)
often become vegans to reduce circulating TMA
and find relief from the disorder9. Utilization of
a plant-based diet to modulate the gut
enterotype and reduce TMAO production may
be the safest and most cost-effective therapy
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currently available to patients with elevated
TMAO and at risk for CVD and other
cardiometabolic disorders. It is currently
unclear how veganism and ovo-lacto-
vegetarianism compare to one another as
effective therapies, but a more strict plant-
based diet may be preferable, as choline is
concentrated in eggs and other dairy
products41,47. While choline is an essential
nutrient for human health, some plant sources
high in dietary choline have not been shown to
exert the same deleterious effect seen from
choline-rich animal products. This may stem
from their effects on the liver enzyme FMO3, as
the choline-rich brussel sprouts were shown
to downregulate FMO3 activity and TMAO
production51. One study also found that
choline-rich pistachios lowered TMAO levels
for those on pistachio-supplemented diets52.
An Ornish-style plant-based diet was also
found to increase plasma betaine levels, but the
association between betaine and CVD risk was
lost without a concomitant rise in TMAO47. On
the contrary, one study showed a diet high in
resistant starch elevated TMAO levels in the
short term53.
Conclusion
Taken together, diet-dependent conversion
of phosphatidylcholine-related metabolites to
TMAO is largely implicated in atherosclerosis
and the progression of cardiovascular disease.
TMAO is purported to exert a deleterious effect
on the arterial endothelium via increased foam
cell formation, inhibited reverse cholesterol
transport and promotion of systemic
inflammation. Clarification of the exact role of
TMAO in these processes as well as
investigation of the causal relationship
between TMAO and chronic diseases like CKD
and T2D are warranted. Limiting the
consumption of animal products rich in choline
and L-carnitine while transitioning to a plant-
based diet may be the safest and most cost-
effective dietary intervention currently
available to those with elevated TMAO levels.
Further randomized controlled trials are
needed to elucidate the long-term impact of a
plant-based diet on gut health and one’s
capacity to produce TMAO.
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